Abstract
The absorption, distribution, metabolism, excretion and the effect on the drug-metabolizing enzyme activities of 1-[bis (4-fluorophenyl) methyl]-4 (2, 3, 4-trimethoxybenzyl) piperazine dihydrochloride (KB-2796) were studied in male rats during and after multiple oral administration at a dose of 2 mg/kg/day. 1. The blood radioactivities at 24 hr after daily administration increased progressively with an increase in the number of dosing, but remained practically constant after the 15th administration. 2. The blood radioactivity reached Cmax of 188.8 ng/ml at 8 hr after the 21st administration, and decreased gradually with the half-life of 67.3 hr. The Cmax and AUC after the 21st administration were 4.4 and 5.7 times greater than those after the 1st dosing, respectively. 3. The extents of cumulative excretion in the urine and feces were almost constant after the 15th administration, and those until 120 hr after the 21st administration were about 9 and 86%, respectively, which were similar with those after the 1st administration. 4. The radioactivity in tissues at 24 hr after daily administration increased with an increase in the number of dosing. After the final administration, a high level of radioactivity was observed in the fat, lung, liver, skin, adrenal and kidney. The elimination of radioactivity from tissues was slow, especially from the aorta. 5. The radioactivity in the brain, liver, lung, spleen, thymus and aorta were present predominantly in the unconjugated fraction. The main metabolites in the tissues were bis (4-fluorophenyl) methylpiperazine (M6) and 4, 4'-difluorobenzophenone (M10), and the unchanged drug was confirmed to be present in all their tissues. 6. The drug-metabolizing enzyme activities were increased after 7 day consecutive oral administration of KB-2796.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.